1. Home
  2. SNDL vs LCTX Comparison

SNDL vs LCTX Comparison

Compare SNDL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SNDL Inc.

SNDL

SNDL Inc.

HOLD

Current Price

$1.53

Market Cap

386.3M

Sector

Health Care

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.63

Market Cap

391.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDL
LCTX
Founded
2006
1990
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
386.3M
391.1M
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
SNDL
LCTX
Price
$1.53
$1.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$5.00
$5.33
AVG Volume (30 Days)
1.3M
992.3K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,556,000.00
Revenue This Year
$6.09
$109.40
Revenue Next Year
$2.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
53.24
52 Week Low
$1.15
$0.40
52 Week High
$2.89
$2.09

Technical Indicators

Market Signals
Indicator
SNDL
LCTX
Relative Strength Index (RSI) 62.49 56.12
Support Level $1.44 $1.56
Resistance Level $1.63 $1.82
Average True Range (ATR) 0.06 0.07
MACD 0.02 0.02
Stochastic Oscillator 94.23 85.11

Price Performance

Historical Comparison
SNDL
LCTX

About SNDL SNDL Inc.

SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: